The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family is central
for Plasmodium falciparum infection. This family mediates interactions between the infected
erythrocyte and the host endothelial surface, making it an obvious vaccine target.
However this family is very diverse, with sixty different variants in the genome of each
parasite. Despite the diversity within the PfEMP1 family, only around ten ligands have
been identified. This suggests that there must be conservation of ligand binding amongst
the sequence variety, which could be targeted in vaccine design strategies.
This thesis explores this possibility, using the interaction between the CIDRα1 domain
within the PfEMP1 and endothelial protein C receptor (EPCR) as an example, as this interaction
has been associated with severe childhood malaria. This thesis details the solution
of the first PfEMP1:ligand crystal structure. The two CIDR:EPCR complex structures
show the binding surface of the CIDR domains to consist of a central hydrophobic residue
which protrudes into a hydrophobic groove in EPCR, surrounded by a ring of hydrophilic
residues. This surface mimics features of the natural EPCR ligand, protein C, and can
block this ligand interaction. Combination of this structure with sequence data from 885
CIDRα1 domains show that the EPCR-binding surfaces of CIDRα1 domains are conserved
in shape and bonding potential, despite dramatic sequence diversity. Having identified
the conserved features of this interaction, three synthetic immunogens were designed to
elicit cross-inhibitory antibodies against this interaction site. The work within this thesis
shows for the first time how the malarial PfEMP1 proteins manage to simultaneously diverge
whilst maintaining the capacity to bind to their ligand, and explores vaccine design
strategies to raise a cross-inhibitory response.</p